Members of the FDA's Medical Imaging Drugs Advisory Committee were nearly universal in their view that the data are not sufficient to tie the use of gadolinium to adverse events in patients with normal renal function, but the panel unanimously backed the agency's proposal to require additional postmarket studies of those contrast agents, which the FDA explicitly said could result in the withdrawal of a contrast agent's approval.